ArticleCurrent oncology (Toronto, Ont.)2026
Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC.
Janne Selke et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.